Matching articles for "Nabilone"

Cannabis and Cannabinoids

   
The Medical Letter on Drugs and Therapeutics • November 18, 2019;  (Issue 1585)
Cannabis (marijuana) contains more than 60 pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best known. THC is the main psychoactive constituent of...
Cannabis (marijuana) contains more than 60 pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best known. THC is the main psychoactive constituent of cannabis. CBD, unlike THC, does not produce intoxication or euphoria.
Med Lett Drugs Ther. 2019 Nov 18;61(1585):179-82 | Show Full IntroductionHide Full Introduction

Nonopioid Drugs for Pain

   
The Medical Letter on Drugs and Therapeutics • February 12, 2018;  (Issue 1540)
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. Use of opioids for pain will be reviewed in a future...
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. Use of opioids for pain will be reviewed in a future issue.
Med Lett Drugs Ther. 2018 Feb 12;60(1540):24-32 | Show Full IntroductionHide Full Introduction

Addendum: Cannabis and Cannabinoids

   
The Medical Letter on Drugs and Therapeutics • August 29, 2016;  (Issue 1502)
A reader asked why our Cannabis and Cannabinoids article (Med Lett Drugs Ther 2016; 58:97) did not include our usual Dosage/Cost table. We have now posted one in the article as it appears online. You can access...
A reader asked why our Cannabis and Cannabinoids article (Med Lett Drugs Ther 2016; 58:97) did not include our usual Dosage/Cost table. We have now posted one in the article as it appears online. You can access it here: www.medicalletter. org/TML-article-1500a.

Download complete U.S. English article

Med Lett Drugs Ther. 2016 Aug 29;58(1502):114 | Show Full IntroductionHide Full Introduction

Cannabis and Cannabinoids

   
The Medical Letter on Drugs and Therapeutics • August 1, 2016;  (Issue 1500)
In the US, 25 states and the District of Columbia now permit some medical use of botanical marijuana (Cannabis sativa). It has been used for centuries to treat various ailments, but non-standardization of...
In the US, 25 states and the District of Columbia now permit some medical use of botanical marijuana (Cannabis sativa). It has been used for centuries to treat various ailments, but non-standardization of dosage makes available data difficult to interpret. Cannabis contains >60 pharmacologically active cannabinoids.
Med Lett Drugs Ther. 2016 Aug 1;58(1500):97-8 | Show Full IntroductionHide Full Introduction

Medical Marijuana

   
The Medical Letter on Drugs and Therapeutics • January 25, 2010;  (Issue 1330)
Fourteen states in the US - Alaska, California, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Jersey, New Mexico, Oregon, Rhode Island, Vermont and Washington - now permit, or soon will permit, some...
Fourteen states in the US - Alaska, California, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Jersey, New Mexico, Oregon, Rhode Island, Vermont and Washington - now permit, or soon will permit, some medical use of marijuana (Cannabis sativa). In some states, licensed facilities dispense botanical cannabis by prescription. In others, limited self-cultivation is permitted for medical use.
Med Lett Drugs Ther. 2010 Jan 25;52(1330):5-6 | Show Full IntroductionHide Full Introduction

Nabilone (Cesamet) for Chemotherapy-Induced Nausea and Vomiting

   
The Medical Letter on Drugs and Therapeutics • December 4, 2006;  (Issue 1249)
Nabilone, an oral synthetic cannabinoid similar to delta-9-tetrahydrocannabinol (THC), the active ingredient in marijuana, has recently been reintroduced to the US market (Cesamet - Valeant) after a 17-year...
Nabilone, an oral synthetic cannabinoid similar to delta-9-tetrahydrocannabinol (THC), the active ingredient in marijuana, has recently been reintroduced to the US market (Cesamet - Valeant) after a 17-year absence. The previous manufacturer discontinued marketing of the drug for commercial reasons. Nabilone is classified as a Schedule II controlled substance.
Med Lett Drugs Ther. 2006 Dec 4;48(1249):103-4 | Show Full IntroductionHide Full Introduction

Ondansentron To Prevent Vomiting After Cancer Chemotherapy

   
The Medical Letter on Drugs and Therapeutics • June 28, 1991;  (Issue 847)
Ondansetron (on dan' se tron; Zofran - Glaxo), a serotonin (5-hydroxytryptamine) antagonist, was recently marketed in the USA for intravenous use to prevent nausea and vomiting due to cancer chemotherapy. An...
Ondansetron (on dan' se tron; Zofran - Glaxo), a serotonin (5-hydroxytryptamine) antagonist, was recently marketed in the USA for intravenous use to prevent nausea and vomiting due to cancer chemotherapy. An oral formulation is available in many other countries.
Med Lett Drugs Ther. 1991 Jun 28;33(847):63-4 | Show Full IntroductionHide Full Introduction

Nabilone And Other Antiemetic For Cancer Patients

   
The Medical Letter on Drugs and Therapeutics • January 1, 1988;  (Issue 756)
Nabilone (Cesamet - Lilly), a synthetic cannabinoid chemically related to tetrahydrocannabinol (THC), the main active ingredient in marijuana, was recently marketed in the USA for oral treatment of nausea and...
Nabilone (Cesamet - Lilly), a synthetic cannabinoid chemically related to tetrahydrocannabinol (THC), the main active ingredient in marijuana, was recently marketed in the USA for oral treatment of nausea and vomiting associated with cancer chemotherapy. Oral THC itself, known generically as dronabinol (Marinol), is also commercially available as an antiemetic for cancer patients (Medical Letter, 27:97, 1985). Other drugs used for this purpose include metoclopramide (Reglan - Medical Letter, 24:67, 1982), prochlorperazine (Compazine; and others), haloperidol (Haldol; and others), and corticosteroids. Benzodiazepines, such as lorazepam (Ativan; and others), are used to treat anticipatory nausea and vomiting that occurs before chemotherapy begins.
Med Lett Drugs Ther. 1988 Jan 1;30(756):2-4 | Show Full IntroductionHide Full Introduction